Biotekselskabet Synact er klar til at starte nyt fase 2-forsøg med selskabets hovedkandidat efter at Lægemiddelstyrelsen og Videnskabsetisk Komité har begge sagt god for studiet.
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
Få fuld adgang til vores kvalitetsjournalistik med et prøveabonnement.
Senior Manager Downstream Manufacturing - Ascendis Pharma
Director, Business Development - Zealand Pharma
Salgschef til Region Sydøst - Nomeco
Compliance Project Manager - Genmab
Senior Manager Drug Product – Ascendis Pharma
Head of In vivo Pharmacology - Zealand Pharma
Manager Process Validation - Ascendis Pharma
CMC Project Manager - Y-mAbs Therapeutics
Head of Medicinal Chemistry - Zealand Pharma
Project Manager CMC - Genmab
Regulatory Affairs Professional - ALK
QA Professional – Drug Substance and Analytical Testing
Director, Regulatory Affairs (Device) - Ascendis Pharma
Regulatory Drug-Device Combination Product Lead – Zealand Pharma
IT QA Manager - Genmab
Sr. Manager Clinical Quality Assurance - Ascendis Pharma
Clinical and Post Market Surveillance Specialist - Ferrosan Medical Devices
Project Manager CMC - Organic Chemist - Ascendis Pharma
Director, Device Development - Ascendis Pharma
Clinical Trial Manager - Genmab
